Chemomab Therapeutics (CMMB) Non Operating Income (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Non Operating Income of -$101000.0 for Q4 2025, down 199.02% on a QoQ basis from $102000.0 in Q3 2025, and up 59.6% year-over-year from -$63283.2 in Q4 2024.
Chemomab Therapeutics (CMMB) Non Operating Income (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at -$101000.0 for Q4 2025.
- Quarterly Non Operating Income rose 59.6% year-over-year to -$101000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $370000.0 (up 25.85% YoY) and the FY2025 annual result came in at $572000.0, down 27.96% from the prior year.
- Non Operating Income was -$101000.0 for Q4 2025 at Chemomab Therapeutics, down from $102000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $480000.0 in Q2 2022 and bottomed at -$431000.0 in Q4 2023.
- A 4-year average of $29400.0 and a median of $137000.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income jumped 198.27% — and 2025, when it plunged 55.07%.
- Chemomab Therapeutics' Non Operating Income stood at -$380000.0 in 2022, then decreased by 13.42% to -$431000.0 in 2023, then surged by 42.0% to -$250000.0 in 2024, then jumped by 59.6% to -$101000.0 in 2025.
- Business Quant data shows CMMB's Non Operating Income at -$101000.0 in Q4 2025, $102000.0 in Q3 2025, and $205000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -101,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Dec 31, 2024 | -250,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 137,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | -431,000.00 |
| Sep 30, 2023 | -231,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Mar 31, 2023 | 317,000.00 |
| Dec 31, 2022 | -380,000.00 |
| Sep 30, 2022 | -237,000.00 |
| Jun 30, 2022 | 480,000.00 |
| Sep 30, 2019 | 12.45 Mn |
| Jun 30, 2019 | -2.77 Mn |
| Mar 31, 2019 | 12.87 Mn |
| Dec 31, 2018 | -1.33 Mn |
| Sep 30, 2018 | 60,000.00 |